WaveMan
WaveMan · Company
FULC · Fulcrum Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

FULC Fulcrum Therapeutics (FULC) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001680581
Quote by TradingView
Form 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
101
13F, latest reported quarter

What the filings say about FULC

Insiders, 180 days
+$1.4M net bought
1 buyer · 1 seller · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$54.4K
1 notice

Fulcrum Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Fulcrum Therapeutics, Inc. insiders bought a net $1.4M of stock across 40 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
TANG KEVIN
BUY
2026-07-20 SECtraded 2026-07-17
50,945
$179.3K
-1.1%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Jul 16, 2026.
  • +4.7% median (+4.7% mean) 90-day return after 4 previous buys.
  • The trade is 0.7% of the 7,080,945 shares held after it.
  • No other insider bought within 30 days.
  • 101 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider TANG KEVIN bought about $179.3K of FULC on Jul 17, 2026; 101 funds added in the latest 13F quarter.
TANG KEVIN
BUY
2026-07-20 SECtraded 2026-07-16
116,671
$415.3K
-1.1%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Jul 15, 2026.
  • +4.5% median (+4.6% mean) 90-day return after 3 previous buys.
  • The trade is 1.7% of the 7,030,000 shares held after it.
  • No other insider bought within 30 days.
  • 101 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider TANG KEVIN bought about $415.3K of FULC on Jul 16, 2026, the largest insider purchase at the company since 2024; 101 funds added in the latest 13F quarter.
TANG KEVIN
BUY
2026-07-15 SEC
107,377
$382.3K
+4.0%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jul 14, 2026.
  • +5.2% median (+5.2% mean) 90-day return after 2 previous buys.
  • The trade is 1.6% of the 6,913,329 shares held after it.
  • No other insider bought within 30 days.
  • 101 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider TANG KEVIN bought about $382.3K of FULC on Jul 15, 2026, the largest insider purchase at the company since 2024; 101 funds added in the latest 13F quarter.
TANG KEVIN
BUY
2026-07-15 SECtraded 2026-07-14
53,651
$191.0K
+4.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jul 13, 2026.
  • The trade is 0.8% of the 6,730,000 shares held after it.
  • No other insider bought within 30 days.
  • 101 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider TANG KEVIN bought about $191.0K of FULC on Jul 14, 2026, the largest insider purchase at the company since 2024; 101 funds added in the latest 13F quarter.
TANG KEVIN
BUY
2026-07-15 SECtraded 2026-07-14
75,952
$271.9K
+4.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jul 13, 2026.
  • The trade is 1.1% of the 6,805,952 shares held after it.
  • No other insider bought within 30 days.
  • 101 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider TANG KEVIN bought about $271.9K of FULC on Jul 14, 2026, the largest insider purchase at the company since 2024; 101 funds added in the latest 13F quarter.
40 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 35 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$1.4M over 180 days
+$1.5M of it by a 10%+ holder
more than 90% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
101 funds bought in last quarter
more than 68% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
10.6% of the float short (float per yahoo 2026-10-27) · 4.7 days to cover · settled 2026-10-15
more than 68% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 6 in the prior 90
Why it matters
The absence is the signal: 6 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch FULC

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-59.3%12M
-65%-22%+20%+63%2025-102025-122026-022026-042026-062026-082026-10 2025-12-08 · RA Capital Healthcare Fund LP sold $38.6M2025-12-08 · RA Capital Healthcare Fund LP sold $18.4M2025-12-08 · RA Capital Healthcare Fund LP sold $1.4M2026-07-16 · TANG KEVIN bought $415.3K2026-07-15 · TANG KEVIN bought $382.3K2026-07-14 · TANG KEVIN bought $271.9K2026-07-14 · TANG KEVIN bought $191.0K2026-07-17 · TANG KEVIN bought $179.3K2025-11-19 · Gould Robert J sold $165.4K2026-01-02 · Gould Robert J sold $163.1K2026-02-02 · Gould Robert J sold $160.8K2026-06-26 · Ezekowitz Alan sold $65.7K2026-07-13 · TANG KEVIN bought $45.9K2025-12-15 · Oltmans Curtis Gale sold $44.6K2026-09-02 · Greg Tourangeau filed to sell $54.4K2026-06-26 · ALAN EZEKOWITZ filed to sell $65.0K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns FULC: institutional holders (13F)

13F holdings, latest reported quarter
Nantahala Capital Management, LLC
10,950,080 sh
$40.1M
BlackRock, Inc.
8,824,259 sh
$32.3M
EcoR1 Capital, LLC
6,549,866 sh
$24.0M
TANG CAPITAL MANAGEMENT LLC
6,521,412 sh
$23.9M
MONTANOVA CAPITAL, LLC
3,680,921 sh
$13.5M

Congress trades in FULC

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

FULC planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Greg Tourangeau
Filed 2026-09-02
$54.4K
ALAN EZEKOWITZ
Filed 2026-06-26
$65.0K

FULC mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$3.0M position · as of 2026-06-30
0.7%
PROFUND VP PHARMACEUTICALS
$77.1K position · as of 2026-06-30
0.7%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$103.9K position · as of 2026-07-31
0.5%
Simplify Health Care ETF
$562.9K position · as of 2026-06-30
0.2%
AVIP BlackRock Advantage Small Cap Growth Portfolio
$86.9K position · as of 2026-06-30
0.1%
BlackRock Advantage Small Cap Growth Fund
$483.4K position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
8 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
0 active
4
Phase 2
1 active
2
Phase 3
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $1.4M bought by insiders over 180 days, 101 funds added last quarter, $54.4K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

FULC financials

Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$66.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-32.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-30.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-36.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-23.8%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$0$80.0M$2.8M$6.3M
Operating income-$84.8M-$21.9M-$110.7M-$112.6M
Net income-$74.9M-$9.7M-$97.3M-$109.9M
EPS (diluted)-1.18-0.16-1.59-2.44
Operating cash flow-$60.1M-$2.2M-$91.0M-$97.0M
Cash$197.5M$58.2M$25.6M$35.1M
SEC XBRL, fiscal years, as known on 2026-10-28

FULC Stock Sonar score 5/7 axes

Find similar shapesCompare

FULC ranks highest on insider conviction (73rd percentile) and profitability (63rd), and lowest on growth (1st), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
63
Inputs
  • Return on equity-32.4% · 66 pct, sector of 545
  • Return on assets-30.8% · 60 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-36.0% · 64 pct, sector of 576
Growth
0
Inputs
  • Revenue growth, YoY-100.0% · 0 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
73
Inputs
  • Net Form 4 buying (codes P and S), 180d$1.4M · 90 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
54
Inputs
  • Funds adding, latest quarter101 · 68 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$190K · 40 pct, sector of 133
Risk and compliance
56
Inputs
  • Short interest, % of float+11.2% · 36 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+6.4% · 75 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

FULC filings, in plain words

Are Fulcrum Therapeutics insiders buying or selling FULC?

In the 180 days to 2026-10-28, Fulcrum Therapeutics insiders were net buyers, a net $1.4M: $1.5M of purchases and $65.7K of sales reported on Form 4, by 1 buyer and 1 seller.

Are there planned insider sales of FULC?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $54.4K of stock; the latest, by Greg Tourangeau, was filed 2026-09-02.

Read the full summary

In the 180 days to 2026-10-28, Fulcrum Therapeutics insiders were net buyers of FULC, a net $1.4M across purchases and sales reported on Form 4 by 1 buyer and 1 seller. Most of that figure, $1.5M, came from a holder of 10% or more rather than an officer or director. Purchases outweighed sales more than tenfold by value. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $54.4K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies